Cialis
Product Images NDC 66336-566

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Cialis (NDC 66336-566). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ndc 66336-0566-xx (Ndc 66336 0566 Xx Eli Lilly)

The image shows a dispensing label for Cialis 20 mg tablets by Dispensing Solutions, Inc. The label indicates each tablet contains 20 mg of tadalafil. It includes storage instructions to keep out of children's reach and store at 77°F. The label also contains warnings and directions such as not to use with nitrates and to avoid excessive alcohol. The label features barcodes, sample lot number and expiration 00-00, the product NDC number 66336-0566, and the labeler's location in Santa Ana, CA.*

FDA Label Image

Chemical Structure (Cialis Uspi F001 Structure V1)

Chemical structure of the active ingredient in Cialis, showing the molecular framework with characteristic rings and functional groups.*

FDA Label Image

Figure (Cialis Uspi F001 V2)

A pharmacokinetic curve showing plasma tadalafil concentration (μg/L) over time (hours) for three dosing regimens: a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg dose after 5 consecutive days. The graph includes error bars for variability and plots concentration decay and steady-state levels across 120 hours.*

FDA Label Image

Figure (Cialis Uspi F002 V1)

Four line graphs showing the difference in blood pressure (BP) measurements between tadalafil and placebo over time in hours (0 to 96). The panels display standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP, with differences in mmHg on the vertical axes and time on the horizontal axes. Error bars indicate variability around each measurement.*

FDA Label Image

Figure (Cialis Uspi F003 V1)

Two line graphs depicting changes in systolic blood pressure (mmHg) over a 24-hour period post-dose. The top graph shows the standing systolic blood pressure for tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg. The bottom graph shows supine systolic blood pressure under the same conditions, with time post-dose in hours on the x-axis and blood pressure change on the y-axis.*

FDA Label Image

Figure (Cialis Uspi F004 V1)

A line graph depicting changes in systolic blood pressure (mmHg) over 12 hours following administration of tadalafil 20 mg and placebo, each combined with 8 mg doxazosin given at 08:00 and 20:00. The x-axis represents time after administration (hours), and the y-axis shows systolic blood pressure changes. Four lines represent different dosing times and treatments.*

FDA Label Image

Figure 5 (Cialis Uspi F005 V1)

A line graph showing the change from baseline in IPSS total score over 12 weeks of treatment. It compares Cialis 5 mg (solid line with dots) and placebo (dashed line with triangles), illustrating greater score reduction with Cialis. An asterisk indicates a statistically significant difference (p<0.01) at 12 weeks.*

FDA Label Image

Figure 6 (Cialis Uspi F006 V1)

A line graph comparing the change from baseline in IPSS Total Score over a 12-week treatment duration between Cialis 5 mg and placebo groups. The x-axis shows treatment duration in weeks (0, 1, 4, 8, 12), and the y-axis shows change from baseline in IPSS Total Score. Cialis 5 mg shows a greater decrease in score compared to placebo, with statistically significant differences indicated at weeks 4 and 12.*

FDA Label Image

Figure 7 (Cialis Uspi F007 V1)

Line graph showing change from baseline in IPSS total score over a 12-week treatment duration. The graph compares Cialis 5 mg with placebo, indicating greater improvement with Cialis. The x-axis represents treatment duration in weeks, and the y-axis shows the change from baseline in IPSS total score.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.